文献速递胃肠外科急腹症与外科感染

胃影葡胺给药时机在粘连性小肠梗阻管理中的意义

Timing of Gastrografin administration in the management of adhesive small bowel obstruction (ASBO): Does it matter?
PubMed 文献 · Surgery · 2021-04-06

非手术患者中早期组住院时间更短、并发症更少、1年死亡率更低;手术患者中早期组术前住院时间更短。

要点

  • 非手术患者早期胃影葡胺组住院时间3.2天 vs 5.4天,并发症和1年死亡率更低
  • 手术患者早期组术前住院时间1.8天 vs 3.9天
  • 建议将早期胃影葡胺挑战方案化

核心结论

  • 粘连性小肠梗阻诊断后12小时内给予胃影葡胺可缩短住院时间、减少并发症和降低死亡率。

主要发现

  • 非手术患者中,早期组住院时间3.2天 vs 5.4天,并发症更少,并发症率和1年死亡率更低(P < .05)。
  • 手术患者中,早期组术前住院时间1.8天 vs 3.9天(P < .05)。
  • 多变量回归显示充血性心力衰竭、任何术后并发症和手术需求是1年死亡率的最佳预测因素(R2 = 0.321;P < .05)。

关键数值与推荐

  • 以住院时间小于5天为预测目标,通过受试者工作特征曲线确定12小时为早期与晚期的分界。

临床怎么用

  • 对粘连性小肠梗阻患者可考虑在诊断后12小时内尽早行胃影葡胺挑战,以缩短住院时间并改善预后。

局限性

  • 回顾性单中心设计,样本量有限,早期与晚期分组基于12小时截断值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrografin challenge is increasingly used as a diagnostic tool to predict patients who may benefit from nonoperative management in adhesive small bowel obstruction. This study explores the optimal timing of Gastrografin in the management of adhesive small bowel obstruction by comparing early versus late Gastrografin challenge. METHODS: A retrospective chart review from January 2016 to January 2018 identified patients with adhesive small bowel obstruction who underwent Gastrografin challenge. A receiver operating characteristic curve, to predict a duration of stay less than 5 days, calculated a 12-hour limit which separated early and late groups. Nonoperative and operative patients were compared separately. Our primary outcome was duration of stay. Secondary outcomes included operative requirement, time to the operating room, complication rate, and 1-year mortality. In a separate analysis, multivariable logistic regression identified independent risk factors for 1-year mortality. RESULTS: One hundred thirty-four patients were identified (58 early, 76 late). In nonoperative patients, the early group had a shorter duration of stay (3.2 days vs 5.4 days), fewer complications, and a lower complication and 1-year mortality rate (P < .05). In operative patients, the early group had a shorter preoperative duration of stay (1.8 days vs 3.9 days) (P < .05). On multivariable regression, congestive heart failure, any postoperative complication, and operative requirement were the best predictors of 1-year mortality (R2 = 0.321; P < .05). CONCLUSION: Gastrografin administration within 12 hours of adhesive small bowel obstruction diagnosis had favorable outcomes in terms of duration of stay, complications, and mortality in nonoperative patients. Moreover, in operative patients, preoperative duration of stay was shortened. Our findings suggest protocolizing early Gastrografin challenge may be an important principle in adhesive small bowel obstruction management.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Cohen RB, Olafson SN, Krupp J, et al. Timing of Gastrografin administration in the management of adhesive small bowel obstruction (ASBO): Does it matter? Surgery. 2021. PMID: 33836900. doi:10.1016/j.surg.2021.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。